FDA Approves NeuroStar Transcranial Magnetic Stimulation for Adolescent Major Depression

The FDA has cleared NeuroStar transcranial magnetic stimulation (TMS) for treating major depressive disorder in adolescents, expanding neuromodulation options for younger patients. This approval provides a non-invasive, drug-free alternative for teens who have not responded adequately to conventional treatments. The decision is expected to broaden access to TMS therapy in pediatric mental health care.

EXPANDED:

The FDA's clearance of NeuroStar TMS represents a notable expansion of neuromodulation into adolescent mental health care. Previously, this non-invasive technology was primarily available to adults, leaving younger patients with major depressive disorder fewer options when conventional treatments proved insufficient. The approval specifically targets teens who have not responded adequately to standard therapeutic approaches.

As a drug-free, non-invasive intervention, TMS offers a distinct alternative to medication-based protocols for this age group. The decision is expected to broaden access to this